Oruka Therapeutics, Inc. ORKA Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Oruka Therapeutics, Inc. (ORKA) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 10.5M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- Oruka Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 22.3% year-over-year, from 8.5M to 10.5M.
- What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
- Represents the number of stock options, warrants, or restricted stock units excluded from the diluted earnings per share calculation because their inclusion would be antidilutive. This metric provides transparency into potential future dilution that is currently masked by the company's net loss position. It is essential for modeling the fully diluted share count once the company becomes profitable.